ARIAD Announces Investor Meeting and Webcast at American Society of Hematology Meeting
CML Expert to Discuss Interim Findings from the PACE Trial on Monday, December 12, 2011 at 7:00 a.m. (PST)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 5, 2011 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host a breakfast meeting with research analysts and institutional investors on Monday, December 12, 2011 at 7:00 a.m. (PST) to discuss the interim data from the pivotal PACE trial of ponatinib, its investigational pan BCR-ABL inhibitor. The event will feature Moshe Talpaz, M.D., Associate Director of Translational Research and Associate Chief of Hematologic Malignancies, Trotman Professor of Leukemia Research at the University of Michigan Medical Center. Dr. Talpaz is an investigator in the PACE trial, as well as the Phase 1 trial of ponatinib.
The investor breakfast meeting is being held at The Westin Gaslamp Quarter Hotel. To attend the meeting, please RSVP to Investor.firstname.lastname@example.org by Wednesday, December 7, 2011. The meeting will also be webcast live and can be accessed by visiting the investor relations section of ARIAD's website at investor.ariad.com or dialing: 866.770.7125 (domestic) or 617.213.8066 (international) and providing the pass code 91497220.
A replay of this investor event will be available on the ARIAD website approximately three hours after the presentation and will be archived for four weeks. To ensure a timely connection to the live webcast, participants should log onto the webcast at least 15 minutes prior to the scheduled start time.
The interim clinical data from the fully enrolled, PACE trial of ponatinib will be presented as an oral presentation at the 53rd Annual Meeting of the American Society of Hematology (ASH) on Sunday, December 11 at 4:30 p.m. (PST). The PACE trial is being conducted in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to nilotinib or dasatinib, two currently available CML therapies, or those who have the T315I mutation of BCR-ABL for which no current treatments are known to be effective.
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD's approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant and difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit http://www.ariad.com.
Posted: December 2011